VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2013

Nov 21, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2013-11-20

Reporting Person: SACHS BRUCE I (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-11-20	Common Stock	S	700	$63.10	Disposed	62410	Direct
2013-11-20	Common Stock	S	800	$64.21	Disposed	61610	Direct
2013-11-20	Common Stock	S	4900	$65.35	Disposed	56710	Direct
2013-11-20	Common Stock	S	1700	$66.25	Disposed	55010	Direct
2013-11-20	Common Stock	S	200	$67.15	Disposed	54810	Direct

Footnotes

F1: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $63.10 (range $62.80 to $63.33).

F3: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $64.21 (range $63.82 to $64.62).

F5: Open market sales reported on this line occurred at a weighted average price of $65.35 (range $64.92 to $65.86).

F6: Open market sales reported on this line occurred at a weighted average price of $66.25 (range $66.00 to $66.80).

F7: Open market sales reported on this line occurred at a weighted average price of $67.15 (range $67.14 to $67.16).